Skip to main content

Table 1 Functional outcomes of eyes with treatment naïve neovascular age-related macular degeneration

From: Visual and anatomical outcomes associated with treat-and-extend administration of intravitreal aflibercept for neovascular age-related macular degeneration

Baseline BCVA, mean  ±  SD 0.92  ±  0.50 logMAR (39.0  ±  24.8 ETDRS letters)
Post-treatment BCVA, mean  ±  SD
 At 6 months 0.74  ±  0.51 logMAR (47.9  ±  25.3 ETDRS letters)
 At 12 months 0.71  ±  0.50 logMAR (49.3  ±  24.9 ETDRS letters)
Mean change in BCVA, mean  ±  SD
 At 6 months − 0.17  ±  0.40 logMAR (+ 8.7  ±  20.2 ETDRS letters)
 At 12 months − 0.20  ±  0.40 logMAR (+ 10.1  ±  20.1 ETDRS letters)
Eyes gaining  ≥  0.3 logMAR units (15 ETDRS letters,  ~  3 Snellen lines), n (%)
 At 6 months 67 (31%)
 At 12 months 72 (34%)
Eyes with  ≤  0.3 logMAR vision (≥  70 ETDRS letters,  ~  Snellen VA  ≥  20/40), n (%)
 At 6 months 39 (18%)
 At 12 months 47 (22%)
  1. BCVA best corrected visual acuity; SD standard deviation; logMAR logarithm of the minimal angle of resolution; ETDRS Early Treatment Diabetic Retinopathy Study; VA visual acuity